Plain-English translation of NCT06008925 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called VG161—a modified virus that is injected directly into stomach cancer tumors—combined with an immune-boosting drug called nivolumab. The study wants to see if this combination is safe and whether it can help patients whose cancer has already spread and stopped responding to previous treatments, including other immune therapies.
Advanced stomach cancer that has spread to other parts of the body is very difficult to treat, especially once it stops responding to standard immune therapies. This trial exists to explore whether directly injecting a virus into the tumors, paired with immune-boosting medication, might offer a new option for patients who have run out of other choices.
The trial has two parts. In Part 1, researchers test different doses of VG161 injected directly into your tumor on days 1–3 of each treatment cycle, along with the immune medication nivolumab given intravenously every two weeks. In Part 2, if the dose is safe, more patients receive the recommended dose. You will have regular blood tests, imaging scans to measure your tumors, tissue biopsies, and clinic visits to check for side effects. The trial lasts for several months, and you may continue treatment if it is helping and you are tolerating it well.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China